SOPH Stock Recent News

BOSTON and ROLLE, Switzerland , July 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter 2025 before U.S. markets open on Tuesday, August 5, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.

Squarepoint Ops LLC lowered its position in SOPHiA GENETICS SA (NASDAQ:SOPH – Free Report) by 30.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,753 shares of the company’s stock after selling 5,886 shares during the quarter. Squarepoint Ops LLC’s holdings in SOPHiA GENETICS were worth $43,000 at the end of the most recent quarter. Other institutional investors have also recently added to or reduced their stakes in the company. Federated Hermes Inc. raised its stake in shares of SOPHiA GENETICS by 40.5% in the 4th quarter. Federated Hermes Inc. now owns 100,000 shares of the company’s stock valued at $312,000 after purchasing an additional 28,819 shares in the last quarter. Dimensional Fund Advisors LP grew its position in SOPHiA GENETICS by 23.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company’s stock worth $6

SOPHiA GENETICS SA. (NASDAQ:SOPH ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Conor McNamara - RBC Capital Markets Subbu Nambi - Guggenheim Operator Good morning, ladies and gentlemen, and welcome to the SOPHiA GENETICS Q1 2025 Earnings Call.

SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago.

BOSTON and ROLLE, Switzerland , May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter  2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basis Gross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectively IFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign exchange P&L impact of $5.2 million), and adjusted EBITDA loss improved 24% year-over-year to $9.8 million The company reiterates full-year guidance of revenue between $72 million and $76 million and adjusted EBITDA loss between $35 million and $39 million "We started the year strong with year-over-year revenue growth of 13%, or 15% on a constant currency basis, as the large amount of new business signed in 2024

BOSTON and ROLLE, Switzerland , April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024 , this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025.

BOSTON and ROLLE, Switzerland , April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.

The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster. BETHESDA, Md.

SOPHiA GENETICS (SOPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BOSTON, MA and ROLLE, Switzerland , March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM™. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatched dataset of diverse, real-world patient data.